Enzymatica AB: First patients included in large placebo-controlled multicentre study on ColdZyme
Press release 30 January 2019 First patients included in large placebo-controlled multicentre study on ColdZyme Enzymatica has initiated a prospective double-blind, placebo-controlled multicentre study to evaluate the effects of ColdZyme® Mouth Spray on the common cold. The study will include 600 patients and is conducted at 10 study centres in Germany. The first patients have now been enrolled in the study, which is expected to be completed during the second half of 2019. The goal of the study is to evaluate clinical effects of ColdZyme on the common cold. The primary objective